Prostate-Cancer Screening — What the U.S. Preventive Services Task Force Left Out
Ces deux articles analysent les récentes recommandations d'un groupe d'experts américains, l'U.S. Preventive Services Task Force, sur l'intérêt du dosage de l'antigène spécifique de la prostate pour la détection d'un cancer chez les hommes asymptomatiques
Forty years after prostate-specific antigen (PSA) was identified and nearly 20 years after it became available for prostate-cancer screening, the U.S. Preventive Services Task Force (USPSTF) recently recommended against PSA-based screening.1 In the interim, untold millions of men have been tested. Because PSA is not cancer-specific and because prostate cancer's aggressiveness varies widely, controversy and debate about PSA screening were predictable from the outset.
Although we agree fully with the task force's analysis, there are three issues that the panel did not address but that are relevant to primary care clinicians, who initiate most PSA screening. (One of us is a general internist who has discussed the pros and cons of PSA screening with hundreds of patients over two decades; the other discovered PSA in 1970.)....
New England Journal of Medicine , article en libre accès, 2010